(5-Amino-2-methoxy-phenyl)-acetic acid methyl ester | 138563-97-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (5-Amino-2-methoxy-phenyl)-acetic acid methyl ester
• 英文别名: Methyl 2-(5-amino-2-methoxyphenyl)acetate
• CAS: 138563-97-0
• 化学式: C₁₀H₁₃NO₃
• 分子量: 195.218
• InChiKey: ZVKOWHUDSUWZLK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (5-Amino-2-methoxy-phenyl)-acetic acid methyl ester 在 三乙烯二胺 、 lithium aluminium tetrahydride 、 碳酸氢钠 作用下， 以 四氢呋喃 、 二氯甲烷 、 异丙醇 为溶剂， 反应 23.0h， 生成
  参考文献：
  名称：

  Discovery of (R)-1-(3-((2-Chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl)piperidin-4-yl [1,1′-Biphenyl]-2-ylcarbamate (TD-5959, GSK961081, Batefenterol): First-in-Class Dual Pharmacology Multivalent Muscarinic Antagonist and β₂ Agonist (MABA) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

  摘要：

  Through application of our multivalent approach to drug discovery we previously reported the first discovery of dual pharmacology MABA bronchodilators, exemplified by 1. Herein we describe the subsequent lead optimization of both muscarinic antagonist and beta(2) agonist activities, through modification of the linker motif, to achieve 24 h duration of action in a guinea pig bronchoprotection model. Concomitantly we targeted high lung selectivities, low systemic exposures and identified crystalline forms suitable for inhalation devices. This article culminates with the discovery of our first clinical candidate 12f (TD-5959, GSK961081, batefenterol). In a phase 2b trial, batefenterol produced statistical and clinically significant differences compared to placebo and numerically greater improvements in the primary end point of trough FEV1 compared to salmeterol after 4 weeks of dosing in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

  DOI：

  10.1021/jm501915g
• 作为产物：
  描述：

  methyl 2-methoxy-5-nitrophenylacetate 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 生成 (5-Amino-2-methoxy-phenyl)-acetic acid methyl ester
  参考文献：
  名称：

  Leaving group effects in reductively triggered fragmentation of 4-nitrobenzyl carbamates †

  摘要：

  报告了通过放射性、酶和化学方法将硝基还原后，一系列取代苯胺从 4-硝基苄基氨基甲酸酯中释放出来的速率和程度。释放出的苯胺的产率在 pH 值为 4-7 的范围内下降，但与离开苯胺的碱性无关。对一个例子的碎裂过程进行的详细研究发现，4-羟胺是关键的中间体。当 pH 值大于 5 时，释放出的苯胺 3b 与反应性 4- 亚氨基喹啉甲烷中间体 4a 缩合，生成胺 26，从而消耗了可测量的苯胺 3b 释放量。当 pH 值小于 5 时，胺的释放会进行到底。还原触发释放苯胺 7 的效率随离去基团的微小变化而变化，但这与苯胺的碱性并不一致。释放出的苯胺 3b 发生竞争反应生成胺 26，从而降低了 3b 的释放效率。这种反应发生在研究中使用的相对较高的浓度（50 μM）下，表明释放的效应胺在浓度大大低于 50 μM 时就会产生毒性。这凸显了在肿瘤定向硝基还原酶酶促药物疗法中使用强效细胞毒性效应物质原药的必要性。

  DOI：

  10.1039/b000135j
• 作为试剂：
  描述：

  3-氨基苯乙酸甲酯 在 吡啶 、 dimethyl sulfide borane 、 (5-Amino-2-methoxy-phenyl)-acetic acid methyl ester 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 14.5h， 生成 3-(N-(4-((2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-ylmethoxy)benzoyl)-N-ethylamino)phenylacetic acid methyl ester
  参考文献：
  名称：

  新型前列腺素D 2受体拮抗剂的设计与合成

  摘要：

  为了确定新的具有成本效益的前列腺素D 2（DP）受体拮抗剂，合成了一系列新型的3-苯甲酰基氨基苯基乙酸，并对其进行了生物学评估。在测试的化合物中，发现有一些代表性的化合物可口服。还评估了受体选择性和大鼠PK谱。提出了结构-活性关系（SAR）研究。

  DOI：

  10.1016/j.bmc.2011.08.007

文献信息

• Leaving group effects in reductively triggered fragmentation of 4-nitrobenzyl carbamates †
  作者：Bridget M. Sykes、Michael P. Hay、Dubravka Bohinc-Herceg、Nuala A. Helsby、Charmian J. O’Connor、William A. Denny

  DOI：10.1039/b000135j

  日期：——

  The rates and extent of release of a series of substituted anilines from 4-nitrobenzyl carbamates, following nitro group reduction by radiolytic, enzymic and chemical methods, are reported. The yield of released anilines decreased over the pH range 4–7, but was independent of the basicity of the leaving aniline. Detailed studies of the fragmentation of one example identified the 4-hydroxylamine as the key intermediate. At pH greater than 5 the released aniline 3b condenses with a reactive 4-iminoquinomethane intermediate 4a to give amine 26, thus depleting the measurable amount of aniline 3b released. At pH less than 5 the release of amine proceeds to completion. The efficiency of reductively triggered release of anilines 7 varied with small changes in the leaving group, but this was not uniformly related to aniline basicity. The competing reaction of the released aniline 3b to form amine 26 lowers the efficiency of release of 3b. This reaction occurs at the relatively high concentrations (50 μM) used in the study and indicates the released effector amine should be toxic at concentrations considerably lower than 50 μM. This highlights the need for prodrugs of very potent cytotoxic effectors to be used in tumour-directed nitroreductase enzyme-prodrug therapy.

  报告了通过放射性、酶和化学方法将硝基还原后，一系列取代苯胺从 4-硝基苄基氨基甲酸酯中释放出来的速率和程度。释放出的苯胺的产率在 pH 值为 4-7 的范围内下降，但与离开苯胺的碱性无关。对一个例子的碎裂过程进行的详细研究发现，4-羟胺是关键的中间体。当 pH 值大于 5 时，释放出的苯胺 3b 与反应性 4- 亚氨基喹啉甲烷中间体 4a 缩合，生成胺 26，从而消耗了可测量的苯胺 3b 释放量。当 pH 值小于 5 时，胺的释放会进行到底。还原触发释放苯胺 7 的效率随离去基团的微小变化而变化，但这与苯胺的碱性并不一致。释放出的苯胺 3b 发生竞争反应生成胺 26，从而降低了 3b 的释放效率。这种反应发生在研究中使用的相对较高的浓度（50 μM）下，表明释放的效应胺在浓度大大低于 50 μM 时就会产生毒性。这凸显了在肿瘤定向硝基还原酶酶促药物疗法中使用强效细胞毒性效应物质原药的必要性。
• US5382590A
  申请人：——

  公开号：US5382590A

  公开（公告）日：1995-01-17
• Investigation of novel 7,8-disubstituted-5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-ones as potent Chk1 inhibitors
  作者：Lisa A. Hasvold、Le Wang、Magdalena Przytulinska、Zhan Xiao、Zehan Chen、Wen-Zhen Gu、Philip J. Merta、John Xue、Peter Kovar、Haiying Zhang、Chang Park、Thomas J. Sowin、Saul H. Rosenberg、Nan-Horng Lin

  DOI：10.1016/j.bmcl.2008.02.080

  日期：2008.4

  The synthesis and structure-activity relationships (SAR) of Chk1 inhibitors based on a 5,10-dihydro-dibenzo[b,e][1,4] diazepin-11-one core are described. Specifically, an exploration of the 7 and 8 positions on this previously disclosed core afforded compounds with improved enzymatic and cellular potency. (C) 2008 Elsevier Ltd. All rights reserved.
• Discovery of (<i>R</i>)-1-(3-((2-Chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl)piperidin-4-yl [1,1′-Biphenyl]-2-ylcarbamate (TD-5959, GSK961081, Batefenterol): First-in-Class Dual Pharmacology Multivalent Muscarinic Antagonist and β₂ Agonist (MABA) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
  作者：Adam D. Hughes、Yan Chen、Sharath S. Hegde、Jeffrey R. Jasper、Sarah Jaw-Tsai、Tae-Weon Lee、Alexander McNamara、M. Teresa Pulido-Rios、Tod Steinfeld、Mathai Mammen

  DOI：10.1021/jm501915g

  日期：2015.3.26

  Through application of our multivalent approach to drug discovery we previously reported the first discovery of dual pharmacology MABA bronchodilators, exemplified by 1. Herein we describe the subsequent lead optimization of both muscarinic antagonist and beta(2) agonist activities, through modification of the linker motif, to achieve 24 h duration of action in a guinea pig bronchoprotection model. Concomitantly we targeted high lung selectivities, low systemic exposures and identified crystalline forms suitable for inhalation devices. This article culminates with the discovery of our first clinical candidate 12f (TD-5959, GSK961081, batefenterol). In a phase 2b trial, batefenterol produced statistical and clinically significant differences compared to placebo and numerically greater improvements in the primary end point of trough FEV1 compared to salmeterol after 4 weeks of dosing in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
• Design and synthesis of new prostaglandin D2 receptor antagonists
  作者：Maki Iwahashi、Eiji Takahashi、Motoyuki Tanaka、Yoko Matsunaga、Yutaka Okada、Ryoji Matsumoto、Fumio Nambu、Hisao Nakai、Masaaki Toda

  DOI：10.1016/j.bmc.2011.08.007

  日期：2011.9

  To identify new cost-effective prostaglandin D2 (DP) receptor antagonists, a series of novel 3-benzoylaminophenylacetic acids were synthesized and biologically evaluated. Among those tested, some representative compounds were found to be orally available. Receptor selectivity and rat PK profiles were also evaluated. The structure–activity relationship (SAR) study is presented.

  为了确定新的具有成本效益的前列腺素D 2（DP）受体拮抗剂，合成了一系列新型的3-苯甲酰基氨基苯基乙酸，并对其进行了生物学评估。在测试的化合物中，发现有一些代表性的化合物可口服。还评估了受体选择性和大鼠PK谱。提出了结构-活性关系（SAR）研究。